Scarica l'app Stockscreener
0.00
100.00%
-4.84
Precedente Chiudi:
$4.84
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$633.18M
Reddito:
$25.81M
Utile/perdita netta:
$-188.12M
Rapporto P/E:
0.00
EPS:
-1.4747
Flusso di cassa netto:
$-183.77M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$6.875
Exscientia Plc Adr Stock (EXAI) Company Profile
Nome
Exscientia Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta EXAI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXAI
Exscientia Plc Adr
|
0.00 | 633.18M | 25.81M | -188.12M | -183.77M | -1.4747 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Exscientia Plc Adr Stock (EXAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-09 | Iniziato | TD Cowen | Buy |
| 2024-01-05 | Downgrade | BofA Securities | Buy → Neutral |
Exscientia Plc Adr Borsa (EXAI) Ultime notizie
Exscientia's SWOT analysis: ai biotech stock faces merger challenges - Investing.com India
Exscientia's SWOT analysis: ai biotech stock faces merger challenges By Investing.com - Investing.com South Africa
Exscientia's SWOT analysis: ai-driven biotech stock faces merger challenges - Investing.com
Exscientia and Recursion Merge to Revolutionize Drug Discovery - TipRanks
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition - Investing.com
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition By Investing.com - Investing.com UK
Recursion, Exscientia shareholders back merger - Investing.com
Such Is The Power Of Verizon Communications Inc (NYSE: VZ) - Stocks Register
Quarterly Metrics: Quick and Current Ratios for Exscientia Plc ADR (EXAI) - The Dwinnex
Exscientia advances two drug programs with Sanofi By Investing.com - Investing.com South Africa
Exscientia advances two drug programs with Sanofi - Investing.com
How to interpret Exscientia Plc ADR (EXAI)’s stock chart patterns - US Post News
Recursion’s All-Stock Acquisition of Exscientia plc (EXAI): NVIDIA-Backed Merger to Revolutionize AI-Driven Drug Discovery - Yahoo Finance
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains? - MSN
Investing in Exscientia Plc ADR (EXAI) might be a great opportunity, but the stock is a bit undervalued - US Post News
Exscientia Plc ADR (EXAI)’s Market Momentum: Closing Strong at 5.06, Down -4.53 - The Dwinnex
Taking on analysts’ expectations and winning: Exscientia Plc ADR (EXAI) - SETE News
Exscientia's SWOT analysis: AI biotech stock faces merger, pipeline milestones - Investing.com
Exscientia Plc ADR (EXAI) expanding its growth trajectory ahead - SETE News
A stock that deserves closer examination: Exscientia Plc ADR (EXAI) - US Post News
Take off with Exscientia Plc ADR (EXAI): Get ready for trading - SETE News
Exscientia Plc ADR (EXAI)’s stock chart: A technical perspective - US Post News
Market Insights: Exscientia Plc ADR (EXAI)’s Notable Gain of 3.78, Closing at 5.22 - The Dwinnex
EXAI’s 52-Week Rollercoaster: From $3.80 to $7.91 – What’s Next for Investors? - The InvestChronicle
Recursion Pharmaceuticals secures key shareholder support - Investing.com
AI biotechs Exscientia and Recursion agree $688m merger - pharmaphorum
Amazon (AMZN) Plunges 19.1% in a Month: Should You Buy the Dip? - Yahoo Finance
Why Do Hedge Funds Think That Exscientia plc (EXAI) Will Skyrocket? - Yahoo Finance
Exscientia takes full control of cancer drug program - Investing.com
Amazon (AMZN) Expands AWS Clientele With Exscientia Deal - Yahoo Finance
How Much Upside is Left in Exscientia (EXAI)? Wall Street Analysts Think 61.43% - Yahoo Finance
Can Exscientia (EXAI) Climb 57.17% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Exscientia (EXAI) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
3 Small-Cap Stocks to Invest in AI Drug Development - TradingView
Exscientia Plc ADR (EXAI)’s financial ratios: A comprehensive overview - The Dwinnex
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
New Strong Buy Stocks for October 25th - Yahoo Finance
Sanofi-Aventis S.A. ADR (SNY-Q) QuotePress Release - The Globe and Mail
Exscientia (NASDAQ:EXAI) shareholders have endured a 55% loss from investing in the stock a year ago - Yahoo Finance
Exscientia Ltd ADR Stock Quote | Stock Price for EXAI - Financial Content
Exscientia (EXAI) Stock Price, News & Analysis - MarketBeat
NVIDIA Corporation (NVDA) Stock Price, News, Quote & History - Yahoo Finance
Exscientia Plc Adr Azioni (EXAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.14%
2.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):